Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of
iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet
Age-related Macular Degeneration (AMD). iSONEP not only has an anti-permeability effect, but
also has anti-angiogenic, anti-inflammatory, and anti-fibrotic properties. The drug may
therefore have the ability to achieve better visual outcomes than Lucentis, Avastin or Eylea,
particularly in those subjects who do not demonstrate a robust response to Lucentis, Avastin
or Eylea after several monthly injections. Further, the combination of Lucentis, Avastin or
Eylea and iSONEP may be additive or synergistic. By inhibiting the multiple mechanisms that
contribute to exudative-AMD-related vision loss, better visual outcomes may be possible than
with Lucentis, Avastin or Eylea alone.